Enrolling Now

InpatientZika 316 Inpatient StudyTo evaluate the clinical and virologic response to escalating doses of 2 different Zika virus strains. The study is recruiting 18-40 year old FEMALES ONLY and involves:

At least 2 screening visits
16 day inpatient stay
11 outpatient follow-up visits following discharge
Use of effective birth control for duration of the study
Up to $4610 for study participation

Milestones

1997-2001//NIH/NCIFirst human trials of a preventive human papillomavirus cervical cancer vaccine (HPV 16). This virus-like particle (VLP) vaccine was the progenitor of the HPV vaccine (Gardasil) recently licensed by the FDA, & of a second vaccine (Cervarix) currently in phase III trials.

2009 / CSL Limited
Principal Investigators and lead site in a large multicenter trial of a pandemic H1N1 influenza vaccine.

2011 / Norovirus Vaccine Against Experimental Human Norwalk Virus Illness
This norovirus VLP vaccine provides protection against illness and infection after challenge with a homologous virus. (Funded by LigoCyte Pharmaceuticals and the National Institutes of Health; ClinicalTrials.gov number.

2012 / ACIP Appointment
Dr. Ruth Karron was appointed to the Advisory Committee on Immunization Practices. The ACIP is a group of medical and public health experts that develops recommendations on how to use vaccines to control diseases in the United States.

2013/ NIH-developed candidate dengue vaccine shows promise in early-stage trialDr. Anna P. Durbin, Principal Investigator, in collaboration with the NIH developed a candidate dengue vaccine. The Phase I clinical trial, launched in July 2010, was conducted in Baltimore; Burlington, VT; and Washington, D.C. The researchers found that all four candidate vaccine combinations induced antibody responses against each of the dengue viruses. However, one vaccine combination, TV003, appeared to induce the most balanced antibody response against the dengue viruses.

2013 / PATH Vaccine Development Program – Shigella vaccine trialDr. Clayton D. Harro, Principal Investigator, in collaboration with PATH Vaccine Development Program and enteric vaccine project, received promising results from a Phase I dose-escalation trial of a monovalent, killed Shigella whole cell vaccine prototype. The vaccine was well tolerated, and 90 percent of the vaccinees receiving the highest dose level developed a statistically significant immune response.

2014 World Vaccine Congress WinnerDr. Anna P. Durbin, Associate Professor at the Center for Immunization Research at Johns Hopkins Bloomberg School of Public Health, is the lead Investigator for Dengue vaccine clinical trials. The Dengue Program is the World Vaccine Congress 2014 winner for “Best Academic Research Team.”